PDL BioPharma, Inc. PDLI

Other  —  Other
Market cap
—
P/E
0.0×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Sep '19 Dec '19 Mar '20 Jun '20
Revenue

+8 more TTM periods

103.44 54.76 54.06 51.81
Cost of Revenue
35.21 53.62 52.68 50.39
Gross Profit
68.23 1.14 1.38 1.42
R&D Expenses
6.91 7.31 8.25 8.83
SG&A Expenses
43.04 54.08 58.31 58.71
Operating Income
25.47 (99.81) (123.47) (127.98)
Non-operating Income/Expense
(32.70) 26.07 12.79 13.88
Non-operating Interest Expenses
11.85 11.40 8.92 6.25
EBT
(7.24) (73.74) (110.68) (114.09)
Income Tax Provision
10.92 (3.05) (16.67) (15.18)
Income after Tax
(18.15) (70.69) (94.01) (98.92)
Net Income Common
0.76 (70.41) (108.81) (154.37)
EPS (Basic)
(0.03) (0.63) (0.94) (1.33)
Gross Margin
65.96% 2.08% 2.55% 2.74%
EBIT Margin
24.62% (182.29%) (228.41%) (247.02%)
EBT margin
(7.00%) (134.67%) (204.75%) (220.22%)
Net Profit Margin
0.73% (128.59%) (201.30%) (297.95%)
Free Cash Flow Margin
63.63% 128.36% (85.48%) (13.21%)
EBITDA
43.10 (82.40) (107.97) (114.58)
EBIT
25.47 (99.81) (123.47) (127.98)
EPS (Diluted, from Cont. Ops)
(0.20) (0.60) (0.79) (0.83)
EPS (Diluted, from Disc. Ops)
— — — 0.00
EPS (Basic, Consolidated)
(0.04) (0.60) (0.91) (1.30)
EPS (Basic, from Discontinued Ops)
— — — (0.17)
EPS (Basic, from Continuous Ops)
(0.20) (0.60) (0.79) (0.83)
Income from Continuous Operations
(18.15) (70.69) (94.01) (98.92)
Income from Discontinued Operations
— — — (19.07)
Consolidated Net Income/Loss
0.42 (70.69) (109.32) (155.13)
EBITDA Margin
41.67% (150.49%) (199.74%) (221.16%)
Operating Cash Flow Margin
(14.85%) (59.25%) (83.98%) (170.98%)

Fold the line items

In millions of $ except per-share values · columns are period end dates